This article is more than 5 years old. Information may no longer be current.
8 news updates to mark IBS Awareness Month
Click Here to Manage Email Alerts
April is IBS Awareness Month, first designated by the International Foundation for Functional Gastrointestinal Disorders in 1997 to spread awareness of the 10% to 15% of Americans who suffer from the symptoms of irritable bowel syndrome.
To add to the discussion of this national awareness initiative, the editors of Healio Gastroenterology compiled eight recent news articles highlighting the latest research and regulatory developments in IBS.
1. Many people with IBS-D symptoms remain undiagnosed
Symptoms related to diarrhea-predominant irritable bowel syndrome significantly impact quality of life, yet a substantial proportion of individuals who meet criteria for IBS-D remain undiagnosed and untreated, according to the results of an online survey. Read more
2. Synergy submits sNDA for CIC drug Trulance to treat IBS-C
Synergy Pharmaceuticals announced it has submitted a supplemental New Drug Application to the FDA for Trulance for the treatment of adults with constipation-predominant irritable bowel syndrome.
“If approved, we believe Trulance will provide an additional, much-needed, new treatment option for people with IBS-C,” Gary S. Jacob, PhD, chairman and CEO of Synergy, said in a press release. Read more
3. Acupuncture significantly benefits IBS patients through 1 year, benefits minimized at 2 years
Acupuncture improved symptoms in patients with IBS that were statistically superior to standard of care through 1 year, but ceased to be significantly superior at 2 years, according to the results of a randomized controlled trial. Read More
4. Cognitive behavior therapy superior to other psychotherapies for improving daily functioning in IBS
Different psychotherapies showed comparable improvements in the mental health of patients with IBS, but cognitive behavior therapy showed the greatest improvements in daily functioning, according to a recently published review and meta-analysis. Read more
5. Gut microbiome marker linked to IBS severity
Researchers have identified an intestinal microbiota signature associated with severity of symptoms in IBS. Read more
6. Clinical trial in IBS begins for cannabis-based chewing gum
Axim Biotechnologies has initiated a clinical trial of its non-prescription hemp-derived cannabinoid functional chewing gum for the treatment of patients with IBS. Read more
7. Functional abdominal pain disorders common in children with IBD
More than a quarter of children with inflammatory bowel disease had overlapping functional abdominal pain disorders, including IBS, in a recent study. Read more
8. Federal report: Evidence lacking on effectiveness of cannabis for IBS
Evidence on the effectiveness of cannabis and cannabinoids for the treatment of IBS is insufficient, and represents a significant research gap that should be addressed by diverse stakeholders, according to a report from the National Academies of Sciences, Engineering, and Medicine. Read more